公开(公告)号：US06890905B2

公开(公告)日：2005-05-10

申请号：US10216349

申请日：2002-08-09

申请人： Hans-Ulrich Demuth ,  Konrad Glund ,  Andrew J. Pospisilik ,  Kerstin Kuehn-Wache

发明人： Hans-Ulrich Demuth ,  Konrad Glund ,  Andrew J. Pospisilik ,  Kerstin Kuehn-Wache

IPC分类号： A61K31/40 ,  A61K31/426 ,  A61K38/00 ,  A61K31/425 ,  A61K31/70

CPC分类号： A61K31/40 ,  A61K31/426

摘要： The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.

摘要翻译： 本发明公开了用于治疗性治疗哺乳动物（包括但不限于人）的方法，以增加内源性胰腺β-细胞的相对胰岛素产生性能，使胰腺上皮细胞分化为产生胰岛素的β细胞，以改善肌肉对 胰岛素和其他体重控制努力通过慢性口服给予DP IV抑制剂。 在生理条件下，给药导致GLP-1和其他非营养刺激生长激素的活性形式在生物活性更长的时间内保持生物活性。 这种激素，特别是胰腺组织的延长存在也可促进已经存在的需要修复的β细胞的分化和再生。